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9 Abstract There is a tremendous need in clinics to impair
10 cancer progression through noninvasive therapeutic ap-
11 proaches. The use of natural compounds to achieve this is of
12 importance to improve the quality of life of young patients
13 during their treatments. This review will address the “status
14 of the art” related to the potential of natural compounds that
15 are undergoing investigation in combination with standard
16 therapeutic protocols in preclinical and clinical studies and
17 their importance for pediatric cancer treatment. The early stud-
18 ies of drug discovery of these natural compounds discussed
19 here include the main targets, the cellular signaling pathways
20 involved, and the potential modes of action. We also focus on
21 some promising natural compounds that have shown excellent
22 results in vitro and in vivo: Chebulagic acid, Apigenin,
23 Norcantharidin, Saffron/Crocin, Parthenolide, Longikaurin
24 E, Lupeol, Spongistatin 1, and Deoxy-variolin B. Additional-
25 ly, we introduce the effects of several compounds from nutra-
26 ceutical and functional foods, to underline their potential use
27 as adjuvant therapies to improve therapeutic benefits. For this
28 purpose, we have selected several compounds: Agaritine,
29 Ganoderma and GL6 peptide, Diallyl trisulfide and Ajoene
30from garlic, Epigallocatechin gallate from green tea,
31Curcumin, Resveratrol, and Quercetin.
32Keywords Anti-cancer drugs . Natural compounds .
33Functional foods . Nutraceuticals . Pediatric tumors . Side
34effects . Tumorigenic pathways
35Abbreviations
37EGCG 8Epigallocatechin gallate
39IAPs 40Inhibitor-of-apoptosis proteins
41RGD 2Arginine–lysine–aspartate 3
44Introduction
45Advances in therapeutic strategies based on small synthetic
46molecules and/or monoclonal humanized antibodies designed
47for inhibition of signaling pathways can often produce toxicity
48in vivo. Thus, the development of non-toxic molecules that
49target specific genes or proteins should be the strategy for the
50near future.
51Natural compounds are small molecules that are produced
52by a biological source, from plants, animals, marine organ-
53isms, andmicroorganisms (Watkins et al. 2015). The introduc-
54tion of natural agents into cancer treatments has been helpful
55for many types of malignancies. Indeed, over 60 % of ap-
56proved anti-tumorigenic drugs derive from natural sources
57(da Rocha et al. 2001, Mann 2002). The anti-tumorigenic
58agents derived from plants and microorganisms currently used
59in clinics in pediatric oncology are listed in Table 1.
60However, not all of the characterization studies of natural
61compounds identified worldwide follow the regulation guide-
62lines. Indeed, only those natural compounds that show a spe-
63cific biologically active ingredient in, for example, a plant
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64 extract, rather than the crude extract, and those for which clear
65 molecular signaling and biological effects are evident should
66 be considered. Moreover, the identification of novel natural
67 extracts must always provide the correct botanical plant and
68 family names from which it is derived, the methods for its
69 extraction, and its physicochemical properties (Michel et al.
70 2005). Taking all of these considerations into account, for the
71 selection of the most promising natural compounds here, we
72 have used this description to include only those that have
73 followed these strict rules. One additional important point is
74 their use in combinatorial therapies, to reduce side effects of
75 defined drugs, with the awareness that they can improve a
76 child’s outcome during treatment.
77 However, the vast majority of the anti-tumor drugs are only
78 approved for the treatment of adults and not for pediatric can-
79 cers. The main reason for this is that targeting pediatric can-
80 cers is a “small market” for investment (Hirschfeld et al.
81 2003). Moreover, pediatric cancers can be driven by molecu-
82 lar mechanisms that are different from those responsible for
83 adult tumors (Smith and Reaman 2015); this makes it more
84 difficult to find specific drugs for childhood tumor treatment.
85 There is a growing body of literature that shows the impor-
86 tance of natural compounds. Indeed, a large number of natural
87 products have been found to inhibit different pathways that
88 contribute to tumorigenesis, angiogenesis, and metastasis in
89 childhood tumors (including those that originate from brain,
90 bone, and liver), both in vitro and in vivo. Their main mech-
91 anisms of action involve disruption of the mitotic spindle as-
92 sembly, inhibition of DNA topoisomerase, arrest of cell-cycle
93 progression, induction of apoptosis, decrease of telomerase
94 activity, and elimination of the “tumor-initiating cells” that
95 are often responsible for chemotherapeutic resistance and tu-
96 mor relapse.
97 Taking all of these observations into account, pediatric tu-
98 mors are generally treated equally following standard proto-
99 cols after surgery, using combined radiotherapy and chemo-
100 therapy. However, restricted therapeutic choices and multi-
101 drug resistance have limited the benefit of many treatments
102 for children because of their devastating side effects, which
103 can include non-selective mechanisms of cell killing (e.g.,
104 young patients have frequently been left with severe
105 myelosuppression); gastrointestinal toxicity; neurological def-
106 icit; endocrine dysfunction; and cognitive difficulties that can
107 lead to postsurgery-related psychological problems (Kinahan
108 et al. 2012); Anderson 2003); (Brydoy et al. 2007). Moreover,
109 complete tumor resection is often difficult, and the responses
110 to radiotherapy and chemotherapy are not always efficient
111 because of the resistance acquired by tumorigenic cells.
112 Another problem is related to the ability of current chemo-
113 therapeutics to pass the blood–brain barrier. Despite aggres-
114 sive and multimodal therapies that have recently been devel-
115 oped, many tumors remain unaffected by these treatments and
116 continue to have poor outcomes for children with metastatic or
117recurrent disease, and thus natural compounds might have the
118potential to fill these gaps ( Q19Giangaspero, Perilongo et al. 1999;
119 Q20Schwab, Westermann et al. 2003;
Q21
Blonski, Taillandier et al.
1202012; Q22Taylor, Northcott et al. 2012;
Q23
Urbanska, Sokolowska
121et al. 2014; (da Rocha et al. 2001, Litten and Tomlinson
1222008, HaDuong et al. 2015). Through their remarkable chem-
123ical and structural diversity, agents derived from natural prod-
124ucts continue to be of relevance as sources of drug leads that
125act as templates for the construction of novel molecules, with
126the challenge being to reduce their side effects (Koehn and
127Carter 2005).
128In this review, we discuss nature-derived drugs that are
129emerging in the treatment of pediatric tumors, through litera-
130ture searches of PubMed (http://www.ncbi.nlm.nih.gov/
131pubmed) for the year 2015, with the scheme applied
132described in Supplementary Figure S1. Most importantly,
133these compounds are considered along with their mechanisms
134of action in tumorigenic cells, for their application as pediatric
135therapies.
136Natural compounds in plants applied to adult clinical
137cancer trials that are of interest for pediatric trials
138The approval of novel anti-cancer drugs for pediatric patients
139usually occurs after their approval for treating adult cancers.
140An ongoing challenge today is to define which agents in de-
141velopment for treating adult cancers have potential therapeutic
142value for childhood cancers. On this basis, several plant-
143derived compounds are currently successfully used in the
144treatment of different types of cancers in adult patients.
145Among these, various natural compounds are proposed as
146candidates for adjuvant treatment of childhood cancers
147(Table 2).
148One of the most promising plant-derived chemopreventive
149agents is Ursolic acid, which is an ursane-type pentacyclic
150triterpenic acid that belongs to the cyclosqualenoid family of
151triterpenoids (Shanmugam et al. 2013). Ursolic acid has been
152reported in leaves and berries of several medicinal plants,
153including Arctostaphylos uva-ursi (L.) Spreng (bearberry),
154Vaccinium macrocarpon Air. (cranberry), Rhododendron
155hymenanthes Makino, Rosmarinus officinalis, Eriobotrya
156japonica, Calluna vulgaris, Ocimum sanctum, and Eugenia
157jambolana. Ursolic acid can have valuable effects in a variety
158of human diseases, including inflammation-driven cancers
159(Shanmugam et al. 2013), and it is well tolerated by adult
160patients with advanced tumors (Zhu et al. 2013). Therefore,
161the idea that Ursolic acid could become a powerful chemopre-
162ventive agent in childhood tumors has been developed. Its
163molecular mechanisms have been studied in hepatoblastoma
164(Son et al. 2013) because of its pro-apoptotic effects in HepG2
165cells (Satomi et al. 2005) and in doxorubicin-resistant HepG2
166cells (Yang et al. 2010). The HepG2 cell line has for several
167years been confused in the literature, with its use as a model of
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168 hepatocellular carcinoma, which is indeed a rare tumor in
169 adults (Aden et al. 1979). Instead, recent studies of compara-
170 tive genomic hybridization and histopathology analyses
171 (Lopez-Terrada et al. 2009) have shown that these cells are
172 indeed epithelia hepatoblastoma, which mainly occurs during
173 the early years of life, in children. Son et al. showed that the
174 Ursolic acid-induced apoptosis in HepG2 cells occurs in a
175 caspase-dependent manner and is regulated by GSK3-β
176 (Son et al. 2013). Their study revealed that in Ursolic acid-
177 treated cells, there was a dose-dependent increase in the inhi-
178 bition of phosphorylation of GSK3-β (on serine 9), which
179 blocked the up-regulation of the pro-apoptotic protein poly
180 (ADP-ribose) polymerase (Son et al. 2013). Furthermore,
181 these data also showed that this apoptosis was regulated by
182 Ursolic acid through the GSK3-β/AKT/mTOR axis, because
183 Ursolic acid not only increased the phosphorylation of
184 GSK3-β but also down-regulated the Akt/mTOR signaling
185 pathway (Son et al. 2013). Ursolic acid has recently been
186 shown to also induce differentiation in the U937 leukemia cell
187 line, with an increase in the levels of specific monocyte sur-
188 facemarkers (i.e., CD14, CD11b) through the activation of the
189 PI3K/Akt pathway (Deng et al. 2014). Moreover, Ursolic acid
190 was less toxic than all-trans retinoic acid, which has already
191 been successfully used as a therapy for acute promyelocytic
192 leukemia (Johnson and Redner 2015). However, the
193 differentiation-inducing effects of all-trans retinoic acid are
194 more efficient than those of Ursolic acid (Deng et al. 2014).
195 Future studies need to determine the exact mechanism of
196Ursolic acid-induced differentiation to promote the develop-
197ment of new pharmacological drugs with higher therapeutic
198effects and lower side effects for the treatment of leukemias
199(Deng et al. 2014). Thus, in conclusion, Ursolic acid repre-
200sents a potential candidate in the treatment of hepatoblastoma
201and leukemia in children through its targeting of apoptosis and
202induction of cell differentiation processes.
203A novel therapeutic strategy to treat hematological malig-
204nancies is seen for the diterpene triepoxide Triptolide, which is
205the major active component in extracts from Tripterygium
206wilfordii Hook F. Triptolide has different pharmacological
207functions, which include anti-tumorigenic effects both
208in vitro and in vivo through down-regulation of anti-
209apoptotic proteins (i.e., XIAP, Mcl-1) and up-regulation of
210pro-apoptotic proteins (i.e., p53, p21, Bax) (Liu et al. 2013).
211The roles of Triptolide in human leukemia cell lines and in
212primary human leukemia blasts have been investigated recent-
213ly (Liu et al. 2013). These data show selective induction of
214caspase-dependent cell death and activation of Rho-associated
215coiled-coil-containing protein kinase ROCK1, which is re-
216sponsible for stabilizing actin microfilaments and promoting
217cell contraction and cell substratum contact (Liu et al. 2013).
218Triptolide has also been demonstrated to induce apoptosis in
219acute lymphoblastic leukemia cells that overexpress the
220MDM2 oncoprotein, through inhibition of MDM2 and XIAP
221expression (Huang et al. 2013).
222Indirubin is another promising natural therapeutic agent
223for hematological malignancies, and it has already been
t2:1 Table 2 Promising natural compounds for pediatric malignancies in clinic trials as anti-cancer agents in adult tumors. The main features of the natural
compounds are given, with reference to their use in adult cancers
Compound Molecular 
structure
Molecular 
formula 
Molecular 
weight
(g/mol)
Tumorigenic cells 
and/or mice models
Evidence
in vitro 
and
in vivo 
Dose
in vitro 
( M)
Dose
In vivo
(mg/kg)
References
Ursolic acid C30H48O3 456.70 Hepatoblastoma
Leukemia
In vitro (Yang, Liu et al. 2010)
(Son, Kwon et al. 2013)
(Deng, Zhang et al. 2014)
Triptolide C20H24O6 360.40 Leukemia In vitro (Liu, Li et al. 2013)(Huang, Zhang et al. 2013)
Indirubin C16H10N2O2 262.26 Leukemia
Glioblastoma
In vitro (Nam, Scuto et al. 2012)
(Williams, Nowicki et al. 
2011)
Epothilone B C27H41NO6S 507.68 Neuroblastoma
Rhabdomyosarcoma
In vitro and 
in vivo
(animal 
models)
(Scherzinger-Laude, 
Schonherr et al. 2013)
Tasidotin C32H58N6O5 606.84 Rhabdomyosarcoma
Ewing’s Sarcoma
Synovial Sarcoma
Osteosarcoma
In vitro and 
in vivo
(animal 
models)
(Garg, Zhang et al. 2007)
O
OH
HO
H
H
H
O
O
O
HO
O
O
N
H
O
NH
O
N
H
O
N
O
N
O
N
O N
O
HN
Salinosporamid A C15H20ClNO4 313.77 Leukemia In vitro 0.0051 (Ruiz, Krupnik et al. 2006)(Niewerth, Jansen et al. 
2014)
HN
O
O
O
HO
Cl
20-30
20-100
_
_
10 _
0.010-
0.100 
1.5
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224 used for the treatment of chronic myeloid leukemia (Xiao
225 et al. 2002). It is an ingredient of the traditional Chinese
226 herbal medicine “Danggui Longhui Wan” which is made
227 from 11 herbal ingredients (Xiao et al. 2002). Indirubin
228 has been shown to inhibit cell growth via the cyclin-
229 dependent kinases (CDKs) in several human cancer cells,
230 by target ing CDK1/cycl in B, CDK2/cycl in A,
231 CDK2/cyclin E, GSK3-β, and CDK5/p25 (Nam et al.
232 2013). Indirubin derivatives have been demonstrated to
233 inhibit the Signal Transducer and Activator of Transcrip-
234 tion member 5 (Stat-5) protein and to down-regulate the
235 expression of its target proteins Bcl-xL and Mcl-1, which
236 are associated with induction of apoptosis (Nam et al.
237 2012). This was shown in human K562 chronic myeloid
238 leukemia cells, in imatinib-resistant human KCL-22 chron-
239 ic myeloid leukemia cells expressing the T315I mutant
240 Bcr-Abl (KCL-22 M), and in CD34-positive primary
241 chronic myeloid leukemia cells from patients (Nam et al.
242 2012). Therefore, Indirubin derivatives represent a promis-
243 ing structural class for the development of new drugs for
244 patients with wild-type or T315I mutant Bcr-Abl-positive
245 chronic myeloid leukemia. Indirubin derivatives might also
246 be useful for the treatment of pediatric solid tumors, be-
247 cause it can reduce the invasion of glioma cells and
248 glioma-initiating cell-enriched neurospheres both in vitro
249 (by modulating β-catenin levels) and in vivo (by improv-
250 ing survival in glioma-bearing mice) (Williams et al.
251 2011). These data suggest that Indirubin offers a novel
252 therapeutic approach that might well be applicable not
253 only in pediatric hematological malignancies.
254 Natural compounds from microorganisms applied
255 to adult clinical cancer trials that are of interest
256 for pediatric trials
257 Microorganisms represent an attractive and advantageous
258 source for the production of medically useful metabolites. In
259 contrast to plants, they can be grown in culture media on a
260 large scale, which provides an unlimited and uninterrupted
261 supply of the raw material needed for drug development. Sev-
262 eral anti-tumorigenic natural compounds have been derived
263 from microorganisms.
264 Epothilones were discovered as secondary macrolide me-
265 tabolites that are produced by the myxobacterium Sorangium
266 cellulosum (Molnar et al. 2000). Like taxanes, epothilones are
267 responsible for microtubule stabilization in vitro (Molnar et al.
268 2000). Patupilone, which is also known as Epothilone B, is a
269 potent microtubule stabilizer that belongs to this class (Molnar
270 et al. 2000). Patupilone binds to β-tubulin with a higher affin-
271 ity than taxanes and alters their spindle formation, which re-
272 sults in the arrest of mitotic cells, and cell death through apo-
273 ptosis (Molnar et al. 2000). In comparison with taxanes,
274 Patupilone has been shown to be more potent in its in vivo
275anti-cancer activity at tolerated dose levels in two pediatric
276tumor mice models of neuroblastoma and rhabdomyosarcoma
277(Scherzinger-Laude et al. 2013).
278Additionally, a liposomal formulation of Patupilone was
279developed and characterized in both in vitro and in vivo
280studies (Scherzinger-Laude et al. 2013). Patupilone has
281been shown to have a strong anti-tumor effect in both of
282these pediatric cancer models, without triggering major
283side effects. These effects were not seen when Patupilone
284was delivered to integrin-expressing cells using RGD lipo-
285somes. Moreover, tumor targeting of liposomal Patupilone
286enhances its anti-tumor activity in rhabdomyosarcoma
287(Scherzinger-Laude et al. 2013). The potent anti-tumor ef-
288fects and the significantly increasing cumulative survival
289of low-dose Patupilone-RGD-liposomes open the way to
290new pharmacological opportunities for targeting liposomes
291as part of low-dose therapeutics in pediatric oncology.
292Natural compounds from marine organisms applied
293to adult clinical cancer trials that are of interest
294for pediatric trials
295Marine organisms are another great source of secondary me-
296tabolites. In the near future, the exploration of marine envi-
297ronments will provide new potential natural compounds. To
298date, the new classes of anti-cancer drugs isolated frommarine
299organisms have been shown to have cytotoxic activities
300against multiple tumor types by targeting different signaling
301pathways.
302The progression of cell growth is inhibited by
303dolastatins, which were originally identified in the Indian
304Ocean sea hare Dolabella auricularia (Garg et al. 2007).
305These are a group of proteins that can inhibit the assembly
306of new microtubules by binding to tubulin and subsequent-
307ly inhibiting tubulin-dependent GTP hydrolysis in vitro
308(Garg et al. 2007). Tasidotin HCl (also known as
309ILX651) is a synthetic pentapeptide (i.e., N,N-dimethyl-
310L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-Lproline-tert-
311butylamide hydrochloride) (Garg et al. 2007). When ad-
312ministered both orally and i.v., Tasidotin has shown strong
313activity in xenograft mice models of breast and ovarian
314cancer, taxane-resistant ovarian cancer, prostate carcino-
315mas, melanoma, non-small cell lung carcinoma, colon car-
316cinoma, and P388 murine leukemia (Mita et al. 2006).
317Several phase I multi-institution clinical trials of Tasidotin
318have recently been completed in adults (Mita et al. 2006),
319although Tasidotin has not yet been explored for the treat-
320ment of pediatric malignancies. With its promising anti-
321neoplastic activity, metabolic stability, and oral bioavail-
322ability, Tasidotin shows potential for broad therapeutic ap-
323plications. Garg et al. investigated the effects of Tasidotin
324in xenograft mice models of pediatric tumors (e.g., rhab-
325domyosarcoma, Ewing’s sarcoma, synovial sarcoma,
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326 osteosarcoma) (Garg et al. 2007). Here, Tasidotin showed
327 significant anti-tumoral activity in all of these mice xeno-
328 graft model studies. These data demonstrate that Tasidotin
329 might have positive effects in the treatment of pediatric
330 sarcomas (Garg et al. 2007).
331 The effects of marine anti-tumorigenic agents have also
332 been tested in other pediatric tumor models, including
333 acute myeloid leukemia, acute lymphoblastic leukemia,
334 and glioma (Potts et al. 2011). Salinosporamide A
335 (Marizomib) is a natural β-lactone-γ-lactam proteasome
336 inhibitor that was derived from the marine actinobacterium
337 Salinispora tropica (Potts et al. 2011). The proteasome
338 represents an important clinical target for the treatment
339 of malignancies, and Marizomib has high specificity for
340 the proteasome by binding and inhibiting all three proteo-
341 lytic protein subunits (i.e., β1, β2, β5) (Potts et al. 2011).
342 A decade ago, the reversible proteasome inhibitor
343 Bortezomib was approved for the treatment of relapsed/
344 refractory and newly diagnosed multiple myeloma and
345 mantle cell lymphoma (Kane et al. 2006), and it represents
346 an emerging treatment strategy for acute leukemia
347 (Messinger et al. 2012, Niewerth et al. 2013). The relevant
348 clinical disadvantages of Bortezomib are related to its un-
349 suitability for oral administration, its toxicity profile, and
350 the emergence of drug resistance (Kale and Moore 2012).
351 Enhanced potency of Salinosporamide A over Bortezomib
352 has been shown in human multiple myeloma cell lines
353 (Chauhan et al. 2005) and in specimens from patients with
354 chronic lymphocytic leukemia (Ruiz et al. 2006).
355 Salinosporamide A might be attractive as a proteasome
356 inhibitor in several malignancies, including acute leukemia.
357 Indeed, tumor cell growth inhibition by Salinosporamide
358 A has been evaluated in human CCRF-CEM acute lym-
359 phocytic leukemia cells and in two of the Bortezomib-
360 resistant sub-lines, CEM/BTZ7 (10-fold resistance to
361 bortezomib) and CEM/BTZ200 (123-fold resistance to
362 Bortezomib) (Niewerth et al. 2014). These findings show
363 that Salinosporamide A is emerging as a potent anti-
364 leukemic agent for both parental and bortezomib-resistant
365 leukemia cells. At this time, further clinical evaluations of
366 its suitability are required.
367 Novel promising plant-derived compounds for pediatric
368 cancer treatment
369 To reduce toxicity and side effects due to current chemother-
370 apeutic regimens, an increasing number of additional nature-
371 derived molecules are currently under investigation to treat
372 pediatric tumors (Table 3). Previously, we highlighted the im-
373 portance of medicinal plants, which have often been investi-
374 gated as sources of new drugs for treating cancer. Due of their
375 low toxicity, plant-derived compounds can effectively reduce
376 the toxicity that is often encountered in vivo.
377Terminalia chebula is a member of the Combretaceae fam-
378ily that is native to India, and it is already being used in alter-
379native medicine (Kumar et al. 2014). One of its major com-
380ponents is the benzopyran tannin Chebulagic acid, the anti-
381tumor effects, and molecular mechanisms of which were stud-
382ied by Kumar et al. in retinoblastoma cells (Kumar et al.
3832014). In recent years, a dramatic change in the management
384of retinoblastoma has occurred, and several methods have
385now been developed, including focal (e.g., cryotherapy, laser
386photocoagulation, transpupillary thermotherapy, plaque
387brachytherapy), local (e.g., external beam radiotherapy, enu-
388cleation), and systemic (e.g., chemotherapy) methods (Pandey
3892014). All of these can lead to terrible complications that can
390include serious detachment, tearing, holding, traction and vas-
391cular retinal occlusion, and focal paraxial lens opacity (Pandey
3922014). Primary enucleation and chemoreduction have become
393the standard care for advanced intraocular retinoblastoma.
394Chebulagic acid treatment decreases the proliferation of Y79
395cells in a dose-dependent manner (Kumar et al. 2014). The
396treated cells underwent apoptosis through increased expres-
397sion of BAX, decreased expression of Bcl2, release of cyto-
398chrome c, and activation of caspase 3 (Kumar et al. 2014).
399Moreover, Chebulagic acid also induced G1 arrest through
400induction of p27 expression and interference with the NFκB
401pathway (Kumar et al. 2014). Chebulagic acid can also exert
402in vitro angiogenic effects by decreasing cell sprouting in the
403treated rat aortic ring and down-regulation of VEGF produc-
404tion and expression of endothelial specific markers (i.e.,
405CD31, E-selectin) (Athira et al. 2013). Further studies will
406be required to determine the efficacy of Chebulagic acid in
407children affected by retinoblastoma and to investigate its
408in vivo anti-tumorigenic effects.
409Among the emerging natural compounds, the naturally oc-
410curring plant flavone (4′,5,7-trihydroxyflavone), or Apigenin,
411has been increasingly recognized as a cancer chemopreventive
412agent because of its remarkable anti-mutagenic, anti-inflam-
413matory, anti-oxidant, and anti-carcinogenic properties (Birt
414et al. 2001). Apigenin is abundant in common fruit and veg-
415etables, including parsley, onions, oranges, tea, chamomile,
416wheat sprouts, and some seasonings (Birt et al. 2001). Several
417studies have reported that Apigenin can induce apoptosis in a
418wide range of tumor cells, including those derived from pedi-
419atric tumors (e.g., leukemia and neuroblastoma cells), through
420different cell signaling and transduction pathways, like NFκB,
421p53, MAPK, and PI3K/Akt (Patel et al. 2007). Wang et al.
422demonstrated that Apigenin has the highest potency among all
423of the flavonoids they tested for the induction of apoptosis in a
424caspase-dependent manner in HL60 leukemia cells (Wang
425et al. 1999). Subsequently, Budhraja et al. showed that
426Apigenin can induce apoptosis in dose-dependent and time-
427dependent manners in U937 cells (Budhraja et al. 2012). Their
428results suggest a hierarchical model of Apigenin-induced ap-
429optosis in human leukemia cells in which Akt inactivation
Naunyn-Schmiedeberg's Arch Pharmacol
JrnlID 210_ArtID 1191_Proof# 1 - 01/12/2015
AUTHOR'S PROOF!
UN
CO
RR
EC
TE
D
PR
O
O
F
430 causes activation of JNK signaling, down-regulation of Mcl-1
431 and Bcl-2, and caspase activation (Budhraja et al. 2012). Fur-
432 thermore, they also demonstrated that this flavonoid can in-
433 hibit tumor growth in vivo, in a U937 cell mice xenograft
434 model (Budhraja et al. 2012). However, the Akt and JNK
435 signaling pathways are not the only targets for Apigenin, be-
436 cause Arango et al. identified other 160 potential targets of
437Apigenin using a phage display system coupled with second
438generation sequencing, an innovative approach that provides
439high-throughput discovery of small molecule–protein interac-
440tions (Arango et al. 2013). They focused on heterogeneous
441nuclear ribonucleoprotein A2 (hnRNPA2), which is an impor-
442tant factor in the progression of tumorigenesis through the
443regulation of splicing, Q24messenger RNA (mRNA) stability,
t3:1 Table 3 Novel natural compounds that can affect several tumorigenic pathways in vitro and/or in vitro in pediatric cancer models. The main features
related to the natural compounds are given, as described in the text, for the promising anti-cancer drugs in pediatric tumors
Compound Molecular 
structure
Molecular 
formula 
Molecular 
weight
(g/mol)
Tumorigenic cells 
and/or mice 
models
Evidence
in vitro
and
in vivo
Dose
in vitro 
( M)
Dose
in vivo 
(mg/kg)
References
Chebulic acid C14H12O11 356.23 Retinoblastoma In vitro (Kumar, Gangappa et al. 2014)
Apigenin C15H10O5 270.23 Leukemia
Neuroblastoma
In vitro 
and
in vivo 
(animal 
models)
(Torkin, Lavoie et al. 2005)
(Budhraja, Gao et al. 2012)
Norcantharidin C8H8O4 168.15 Medulloblastoma
Glioblastoma
Leukemia
Hepatoblastoma
In vitro 
and
in vivo 
(animal 
models)
(Cimmino, Scoppettuolo et al. 
2012)
(Zheng, Du et al. 2014)
(Liao, Chen et al. 2011)
(Lu, Gao et al. 2014)
Crocin C44H64O24 976.96 Hepatoblastoma
Leukemia
In vitro 
and
in vivo 
(animal 
models)
(Noureini and Wink 2012)
(Sun, Xu et al. 2013)
Parthenolide C15H20O3 248.32 Hepatoblastoma
Glioblastoma
In vitro 
and
(Sun, Zhang et al. 2014)
(Nakabayashi and Shimizu 2012)
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HO OH
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HO
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HO
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Leukemia
Osteosarcoma
in vivo 
(animal 
models)
(Guzman, Rossi et al. 2005)
(Diamanti, Cox et al. 2013)
(Kishida, Yoshikawa et al. 2007)
Longikaurin E C22H30O6 390.47 Pancreatic tumor In vitro (Cheng, Bo et al. 2015)
Lupeol C30H50O 426.73 Pancreatic tumor
Osteosarcoma
In vitro 
and
in vivo 
(animal 
models)
(Liu, Bi et al. 2015)
(Liu, Bi et al. 2015)
Okadaic acid C44S68O13 805 Retinoblastoma
Neuroblastoma
In vitro (Di Fiore, Drago-Ferrante et al. 
2013)
(Edelstein and Rockwell 2012)
Spongistatin 1 C65H99ClO20 1235.92 Leukemia In vitro (Schyschka, Rudy et al. 2008)
Variolin b C14H11N7O 29328 Leukemia In vitro (Simone, Erba et al. 2005)
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50 _
40-60 20-40
25-100 1-10
600-5000 6.25-25
5-10 10-40
0,5-4 _
7.5-120 30-60
0.005-0.050 _
0.0002-
0.001
_
0.050-0.10 _
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444 and mRNA transport (Arango et al. 2013). High expression of
445 hnRNPA2/B1 has been reported in a variety of human cancers
446 (Zhou et al. 2001), including glioblastoma (Golan-Gerstl et al.
447 2011). Arango et al. established that by interacting with the C-
448 terminal domain of hnRNPA2, Apigenin inhibits hnRNPA2
449 dimerization and alters the alternative splicing patterns of the
450 hnRNPA2 substrates in breast cancer cells (Arango et al.
451 2013). Indeed, the addition of Apigenin to malignant cells
452 reverts the splicing of caspase-9 and cellular FADD-like IL-
453 1β-converting enzyme (FLICE)-inhibitory protein (c-FLIP),
454 which are two key regulators of apoptosis, without acting
455 against the splice variants in non-carcinogenic cells (Safa
456 2012). These results might help to explain how Apigenin
457 has an anti-carcinogenic activity by decreasing the inhibition
458 of apoptosis (Arango et al. 2013). The effects of Apigenin
459 have also been studied in human neuroblastoma cells. Torkin
460 et al. reported that Apigenin inhibits tumor growth and in-
461 duces caspase-dependent apoptosis not only in vitro but also
462 in a non-obese diabetic/severe combined immunodeficient
463 (NOD/SCID) mouse xenograft model, using NUB-7 im-
464 planted tumors (Torkin et al. 2005). Apigenin induced p53
465 nuclear accumulation, thus leading to increased expression
466 of its target proteins (i.e., p21, Bax) (Torkin et al. 2005).
467 Due to its apoptotic effect being restricted to tumorigenic cells
468 without toxicity shown to non-transformed neuronal cells,
469 Apigenin emerged in this study as a potential compound for
470 further development as a therapeutic agent for patients with
471 neuroblastoma.
472 Cantharidin is a natural compound that was originally iso-
473 lated from beetles, and it is one of the most emergent anti-
474 tumorigenic agents because of its broad therapeutic applica-
475 tions across a large number of pediatric tumors (Torbeck et al.
476 2014). The clinical use of Cantharidin has, however, been lim-
477 ited, because of its severe side effects, with analogs of Canthar-
478 idin synthesized to reduce this toxicity. Cantharidin and its
479 derivatives have been shown to have strong in vitro anti-
480 tumor activities. Norcantharidin is a demethylated form of Can-
481 tharidin, and it has already been used as a routine anti-cancer
482 drug in China (Chen et al. 2005). Norcantharidin showed lower
483 toxicity toward normal cells and was more effective in anti-
484 cancer activities (Chen et al. 2005, Liao et al. 2007). Canthar-
485 idin and Norcantharidin express their anti-cancer activities
486 through inhibition of protein phosphatase 1 (PP1) and PP2A,
487 which are involved in cell-cycle progression. Norcantharidin is
488 active in vitro against several tumor cell lines, including hepa-
489 toma and leukemia cell lines, and its cytotoxic action has been
490 demonstrated to be approximately 10-fold less than that of
491 Cantharidin in many of these cell lines (Tarleton et al. 2012).
492 Norcantharidin has also shown potent anti-metastatic and anti-
493 angiogenic effects through inhibition of cell migration and
494 capillary-like tube formation in HUVEC cells, by decreasing
495 the amount of pro-angiogenic secreted soluble factors (e.g.,
496 angiogenin, GRO, IGF-1, IL-8, MCP-1, VEGF), and without
497significant toxicity (Chen et al. 2009). This inhibition was ac-
498companied by anoikis, down-regulation of integrin β1, and
499breakdown of vimentin (Chen et al. 2009). Moreover, in vivo
500experiments have demonstrated that Norcantharidin prolonged
501the survival and reduced the plasma VEGF levels in mice with
502pulmonary metastasis without showing significant renal and
503liver toxicity (Chen et al. 2009). Therefore, with its ability to
504pass through the blood–brain barrier, Norcantharidin has been
505investigated for pediatric brain tumors in vitro and in vivo. In
506medulloblastoma cell lines, Norcantharidin treatment impaired
507the growth of DAOY and UW228 cells by affecting Wnt/β-
508catenin signaling through nuclear β-catenin loss (Cimmino
509et al. 2012). The efficacy of Norcantharidin to decrease medul-
510loblastoma tumor growth was also assessed in vivo using me-
511dulloblastoma orthotopic brain-cerebellum xenograft animal
512models. These results showed significantly reduced tumor size
513in the treated mice (Cimmino et al. 2012). Norcantharidin also
514inhibited cell growth by impairment of the Raf/MEK/ERK
515pathway in a dose-dependent manner, and it induced apoptosis
516in glioma cells through down-regulation of the pro-apoptotic
517proteins Bcl-2 and Mcl-1 (Zheng et al. 2014). Liao et al. devel-
518oped a model to induce cancer progression via PMAI in a
519human T cell leukemia cell line and then defined the mecha-
520nisms behind Norcantharidin for the inhibition of cell growth
521and induction of cell-cycle arrest (Liao et al. 2011). The results
522of this study showed that Norcantharidin can significantly in-
523hibit the viability of these treated cells by induction of cell-cycle
524arrest at the G2/M phase, down-regulation of the expression of
525calcineurin, and attenuation of interleukin (IL)-2 production
526(Liao et al. 2011). These results provide important information
527about the possible use of Norcantharidin as a chemopreventive
528agent to inhibit leukemia progression (Liao et al. 2011). Re-
529cently, Norcantharidin was shown to have anti-tumor activity
530also through modulation of the tumor microenvironment in
531hepatocellular carcinoma models (Lu et al. 2014). Macro-
532phages are known to take part in the tumor microenvironment
533and to have a dual role in tumor development and progression
534(Lamagna et al. 2006). Classically, activated M1 macrophages
535have anti-tumor effects through the release of pro-inflammatory
536cytokines. On the contrary, alternatively activated M2 macro-
537phages facilitate the progression of tumors, through the release
538of anti-inflammatory cytokines (Sica et al. 2008). As a result,
539tumor-associated macrophages have been the target for cancer
540treatments. Norcantharidin inhibited tumor growth in
541hepatoma-bearing mice through the β-catenin signaling path-
542way and subsequently by shifting fromM2 macrophage to M1
543macrophage polarization (Lu et al. 2014).
544In hepatoblastoma, in addition to Norcantharidin, the anti-
545tumorigenic effects of Crocus sativus L. which is commonly
546known as Saffron have been investigated. This natural com-
547pound comes from this perennial stem-less herb of the large
548Iridaceae family that has been widely studied over the last
549decade for its biomedical properties (Abdullaev et al. 2003).
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550 Chemopreventive potential of Saffron against cancer and the
551 absence of toxicity and mutagenicity have been reported. In-
552 deed, Saffron appears to have cytotoxic activity against differ-
553 ent tumorigenic cells, while no inhibitory effects are seen on
554 normal cell growth (Abdullaev et al. 2003). Crocin is the main
555 water-soluble carotenoid of Saffron extracts, and it represents
556 the most promising Saffron constituent as a therapeutic agent
557 against cancers (Escribano et al. 1996). One of its anti-
558 tumorigenic effects relates to telomerase activity. In
559 hepatoblastoma cell lines, Crocin has been shown to decrease
560 telomerase activity by down-regulation of the expression of
561 hTERT, the catalytic subunit of telomerase (Noureini and
562 Wink 2012). As the telomerase activity is high in cancer cells
563 and almost undetectable in normal cells, it might be a selective
564 target in pediatric cancer therapy. Inhibition of telomerase
565 would selectively suppress tumor growth without large effects
566 on normal cells. Crocin anti-tumor effects have also been in-
567 vestigated in human leukemia cells, both in vitro and in vivo.
568 HL-60 leukemia cells treated with Crocin showed a reduced
569 proliferation rate and induction of apoptosis (Sun et al. 2013).
570 Moreover, daily intraperitoneal injections of Crocin inhibited
571 the growth of leukemia cells in nude mice through modulation
572 of the expression of the apoptosis-related molecules Bcl-2 and
573 Bax (Sun et al. 2013). These findings suggested a potential
574 role for Crocin in the treatment of leukemia.
575 Parthenolide is another promising plant-derived candidate
576 for cancer chemoprevention. This is a sesquiterpene lactone
577 that was originally purified from the shoots of the feverfew,
578 Tanacetum parthenium (Ghantous et al. 2013), that has shown
579 anti-cancer and anti-inflammatory activities in several cell
580 lines derived from pediatric tumors (Gach et al. 2015). These
581 biological properties of Parthenolide can be attributed to its
582 strong inhibition of NFκB (Bork et al. 1997). It was also
583 shown recently that Parthenolide can induce growth inhibi-
584 tion, autophagy, and caspase-mediated cell death in
585 hepatoblastoma cells (Sun et al. 2014). Further, Parthenolide
586 has been shown to suppress cell proliferation and invasion,
587 and tumor-induced angiogenesis in vitro, and to inhibit
588 neovascularity and tumor growth in vivo in glioblastoma mice
589 models (Nakabayashi and Shimizu 2012). It has been sug-
590 gested that this anti-tumor function of Parthenolide might be
591 mediated not only by inhibition of NFκB but also by inhibi-
592 tion of Akt signaling (Nakabayashi and Shimizu 2012). It is of
593 note that Parthenolide effectively eradicated acute myeloid
594 leukemia stem cells and progenitor cells in vitro while sparing
595 normal hematopoietic stem cells (Guzman et al. 2005). Thus,
596 Parthenolide has been investigated as a potential chemothera-
597 peutic agent in acute myeloid leukemia and acute B-
598 lymphoblastic leukemia cells (Guzman et al. 2005). Treat-
599 ments for pediatric patients with leukemia are now increasing-
600 ly successful. However, approximately 20 % of children with
601 acute lymphoblastic leukemia relapse because of the failure to
602 eradicate the disease, and most of these patients do not
603survive. Parthenolide was reported for the first time to eradi-
604cate multiple leukemia-initiating cell populations in vivo in
605childhood acute lymphoblastic leukemia (Diamanti et al.
6062013). For this reason, Parthenolide might have therapeutic
607potential in childhood acute lymphoblastic leukemia, which
608would provide a basis for the development of effective thera-
609pies that can eradicate leukemia-initiating cell populations, to
610prevent disease progression and reduce relapse (Diamanti
611et al. 2013). Osteosarcoma is a highly aggressive primary
612bone tumor that predominantly affects children and typically
613demonstrates significant resistance to radiotherapy (Fuchs and
614Pritchard 2002). Consequently, the conventional treatments
615do not prevent metastatic progression in 30 to 40% of patients
616(Lisle et al. 2008). To obtain more effective treatments, it
617might be necessary to target the mechanisms used by osteo-
618sarcoma cells to acquire significant resistance to radiotherapy.
619This radio-resistance in the SaOS2 osteosarcoma cell line has
620been demonstrated to be subsequent to up-regulation of NFκB
621(Eliseev et al. 2005). As Parthenolide affects NFκB (Kishida
622et al. 2007), it can potentially provide a clinical method to
623decrease NFκB in patients with osteosarcoma, which would
624allow the radiation therapy to have an effective role in this
625cancer treatment. The in vitro treatment of these re-
626sensitized cancer stem cells and the entire cell population with
627radiotherapy has also been investigated in osteosarcoma. The
628results have indicated that Parthenolide and ionizing radiation
629act synergistically to induce cell death in LM7 osteosarcoma
630cells (Zuch et al. 2012). When used together with the stan-
631dard therapeutic regimen, Parthenolide has been pro-
632posed to increase the sensitivity of these cancerous cells
633to radiotherapy, to provide more complete eradication of
634the malignant tissue. In conclusion, Parthenolide has
635been identified as a new therapeutic agent for glioblas-
636toma, leukemia, and hepatoblastoma in children, al-
637though the promise that Parthenolide holds for therapy
638is still limited. This is because of different factors, in-
639cluding its off-target effects and hydrophobicity, which
640limits its solubility, and thus its oral bioavailability. In
641the near future, new strategies will be implemented in-
642volving low pharmacological doses of Parthenolide ei-
643ther alone or in combination with other drugs, which
644will define its anti-tumorigenic potential both in vitro
645and in vivo.
646Longikaurin E is a novel natural compound that is derived
647from the herbal medicine Rabdosia longituba (Cheng et al.
6482015), and that has shown anti-proliferative and pro-apoptotic
649effects in pancreatic cancer cell lines (Cheng et al. 2015).
650Pancreatic tumors are very rare at pediatric ages, and surgery
651remains the keystone to treat this tumor in children, as in
652adults (Dall'igna et al. 2010). Cheng et al. showed that
653Longikaurin E induces apoptosis of pancreatic cancer cells
654by up-regulation of Bax and down-regulation of Bcl-xL,
655Bcl-2, Survivin, and c-Myc (Cheng et al. 2015). They also
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656 reported increased p38 phosphorylation and inhibition of the
657 PI3K/Akt pathway in the treated cells. Although the anti-
658 tumorigenic effects of Longikaurin E were observed in pan-
659 creatic cancer cell lines derived from adult tumors (i.e.,
660 PANC1, ASPC-1, and BxPC-3 human pancreatic cancer
661 cells), Longikaurin E has emerged as a new drug with poten-
662 tial applications also for pancreatic cancer in children (Cheng
663 et al. 2015). Further studies will be necessary to test its anti-
664 cancer effects on primary pancreatic tumorigenic cells derived
665 from patients of pediatric ages before its clinical application.
666 In pancreatic cancer, in addition to Longikaurin E, the anti-
667 tumorigenic effects of Lupeol, a dietary triterpene, have been
668 investigated (Q25 Liu et al. 2015a, b). Lupeol is found in fruit (such
669 as olives, mangos, strawberries, grapes, and figs), in vegeta-
670 bles, and in medicinal plants (Chaturvedi et al. 2008). Liu
671 et al. showed that Lupeol has anti-proliferative and pro-
672 apoptotic effects on pancreatic cancer both in vitro and
673 in vivo (Liu et al. 2015a, b). Lupeol induced cell-cycle arrest
674 by up-regulation of p21 and p27 and down-regulation of cy-
675 clin D1. Interestingly, following Lupeol treatment in vivo,
676 they showed decreased tumor growth and down-regulation
677 of p-ERK and p-Akt in tumor tissues (Liu et al. 2015a, b).
678 Lupeol has also been reported to have anti-cancer efficacy
679 against chemoresistant pancreatic cancer cells through modu-
680 lation of TRAIL/cFLIP, both in vitro and in vivo in athymic
681 mice (Murtaza et al. 2009). The anti-cancer effects of Lupeol
682 have also been investigated in osteosarcoma, where it induced
683 apoptosis and cell-cycle arrest of human osteosarcoma cells
684 by targeting the PI3K/Akt/mTOR pathway (Liu et al. 2015a,
685 b). Moreover, Lupeol administration in vivo decreased tumor
686 growth and had no effects on the function of the liver and
687 kidneys (Liu et al. 2015a, b). These data suggested a potential
688 role for Lupeol in the treatment of pancreatic cancer and
689 osteosarcoma.
690 Novel promising marine compounds for pediatric cancer
691 treatment
692 The development of marine natural compounds is progressing
693 actively, with a significant number of anti-tumor compounds
694 that are entering preclinical studies and early clinical evalua-
695 tion. About 3000 new compounds have been identified from
696 marine organisms due to advances in deep-sea collection and
697 “aquaculture” technology, which demonstrates that the sea
698 represents a huge potential source for drug discovery (da
699 Rocha et al. 2001).
700 Several phytoplanktonic species accumulated by shellfish
701 are responsible for the production of Okadaic acid, a lipophilic
702 toxin that causes human diarrheic shellfish poisoning, which
703 although not lethal, causes gastrointestinal symptoms that in-
704 clude diarrhea (92 %), nausea (80 %), vomiting (79 %), ab-
705 dominal pain (53 %), and chills (10 %) (Valdiglesias et al.
706 2013). These symptoms vary according to the dose of toxin
707ingested. The minimum dose of Okadaic acid responsible for
708this poisoning in human is about 40 mg (Valdiglesias et al.
7092013). Several classes of protein serine/threonine phospha-
710tases that regulate cell growth, division, and death and main-
711tenance of the cytoskeletal structure are targets of this toxin.
712Indeed, Okadaic acid might cause inhibition of protein phos-
713phatases, particularly PP1 and PP2A, but also other types,
714including PP4, PP5, and PP2B (Louzao et al. 2005). The most
715reported cytotoxic effect of Okadaic acid is apoptosis induc-
716tion, while it is known to cause growth inhibition and apopto-
717sis and to induce oxidative stress in different cell types
718(Valdiglesias et al. 2013). Nevertheless, the genotoxic and
719cytotoxic effects caused by Okadaic acid might be responsible
720for genomic instability that can lead to severe pathologies,
721including cancer (Valdiglesias et al. 2013). Despite these cy-
722totoxic and genotoxic effects, Okadaic acid might still repre-
723sent a novel candidate for neuroblastoma and retinoblastoma
724treatment in children. Edelstein et al. showed that in neuro-
725blastoma cells, PPA2 inhibition by Okadaic acid induced Akt
726hyperphosphorylation, increased levels of ubiquitinated pro-
727teins, oxidative stress, loss of cell viability, and cell death
728(Edelstein and Rockwell 2012). Furthermore, they demon-
729strated that Rapamycin can enhance Okadaic acid-induced
730Akt phosphorylation, to increase the susceptibility of cells to
731pro-oxidant cell death caused by Okadaic acid (Edelstein and
732Rockwell 2012). The effects of Okadaic acid in combination
733with Parthenolide were investigated in human retinoblastoma
734cells (Di Fiore et al. 2013). These two compounds acted to-
735gether to induce cytotoxicity in Y79 cells by lowering p-Akt
736levels, stabilizing p53, increasing reactive oxygen species, and
737concurrently lowering glutathione content (Di Fiore et al.
7382013). These results provide strong support for a combined
739treatment approach to target the PTEN/Akt/mDM2/p53 path-
740way in this childhood tumor (Di Fiore et al. 2013). The mo-
741lecular effects of Okadaic acid appear to be cell-type depen-
742dent. Valdiglesias et al. showed that Okadaic acid can produce
743oxidative DNA damage both in human peripheral leukocytes
744and human neuroblastoma cells but not in human
745hepatoblastoma cells (Valdiglesias et al. 2011). They conclud-
746ed that the mechanism leading to DNA damage is highly
747dependent on cell type. Other studies will be necessary to
748identify the exact mechanisms of action of Okadaic acid in
749different tumorigenic cell lines.
750Spongistatin 1 is a macrocyclic lactone that was isolated
751from the marine sponges Spirastrella spinispirulifera and
752Hyrtios erecta as a cytotoxic antimitotic compound (Bai
753et al. 1993). It can block the cell cycle in the mitotic phase
754in L120 murine leukemia cells (Bai et al. 1993). Spongistatin
7551 has been shown to induce cell death in Jurkat leukemia T
756cells and, more importantly, in primary acute leukemic cells
757derived from patients (Schyschka et al. 2008). Furthermore,
758inhibitor-of-apoptosis proteins (IAPs) are overexpressed in
759cancer cells and in primary tumor biopsy samples (Salvesen
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760 and Duckett 2002). Drugs designed to specifically target these
761 anti-apoptotic proteins might be valuable to overcome
762 chemoresistance. Of note, Spongistatin 1 can induce
763 protein degradation of the X-linked XIAP, thus
764 impairing the XIAP-overexpressing function in Jurkat
765 cells, and therefore targeting an important molecular
766 key in the apoptosis resistance of tumorigenic cells
767 (Schyschka et al. 2008).
768 Variolin B is a novel marine natural product that was
769 isolated from the sponge Kirkpatrickia variolosa, which is
770 found in Antarctica (Dembitsky et al. 2005). As it has
771 been shown to have pro-apoptotic activity, Variolin B rep-
772 resented a new potent natural cytotoxic agent (Dembitsky
773 et al. 2005). The use of Variolin B is limited by its low
774 stability in solution. However, the development of a
775 Deoxy-variolin B analog that is much more stable and
776 soluble has overcome this limitation of the parent com-
777 pound (Anderson et al. 2005). The biological activity of
778 this deoxy analog was similar to that of Variolin B, with a
779 slight increase in potency of the deoxy analog that is
780 likely to be related to its greater stability and solubility
781 (Anderson et al. 2005). The biological properties of
782 Variolin B and its deoxy analog, and their mechanisms
783 of action, have been investigated in detail in several tu-
784 morigenic cells, including the K562 human leukemic and
785 Jurkat cell lines (Simone et al. 2005). Both of these com-
786 pounds inhibited colony formation and caused cell-cycle
787 perturbations through increased p53 tumor suppressor
788 protein function and p21, thus definitively inducing apo-
789 ptosis (Simone et al. 2005). However, the increase in p53
790 appears to be due to cellular stress induced by the dose of
791 the treatment and does not appear to be crucial for the
792 biological effects of Variolin B and its deoxy analog. In-
793 deed, there were no differences seen in vitro in comparing
794 the cytotoxicity combined with the cell-cycle perturba-
795 tions induced by Variolin B and its deoxy analog in cell
796 lines expressing wild-type p53 and within sub-lines that
797 had no p53 expression or contained an inactivated p53
798 isoform (Simone et al. 2005). Moreover, Variolin B and
799 its deoxy analog prevented the cells from entering S phase
800 by inhibition of the CDK1/cyclin B, CDK2/cyclin A, and
801 CDK2/cylin E complexes (Simone et al. 2005). In conclu-
802 sion here, these Variolins can be considered as a new class
803 of CDK inhibitors that activate apoptosis in a p53-
804 independent manner, and thus they might be effective
805 against not only pediatric tumors but also several cancers
806 with p53 mutations or deletions.
807 Altogether, the data here reported support the idea that
808 among marine and herbal-derived compounds, there is a vari-
809 ety of potentially effective anti-cancer agents that can act on
810 several key targets of the tumorigenic processes. Future stud-
811 ies need to be performed soon to address their properties
812 in vivo, to support new clinical trials in childhood cancers.
813Nutraceutical and functional foods as anti-cancer drugs
814to support pediatric cancer treatment
815Several natural compounds ingested in the diet are known to
816have anti-tumorigenic effects. As many nutraceuticals and
817functional foods have been demonstrated to have anti-cancer
818actions, they might represent novel agents for the treatment of
819pediatric cancers (Table 4). Q26
820Among the nutraceuticals, mushrooms contain a large
821number of compounds that can target different pathways that
822are responsible for cancer progression, which include those
823that modulate the tumor microenvironment. Jiang et al. pro-
824vided a complete list of mushrooms that have been shown to
825target cancer cells and, in particular, tumorigenic cells derived
826from pediatric tumors (Jiang et al. 2015).
827The Basidiomycete fungus Agaricus blazei Murill is an
828edible mushroom that is cultivated in Japan, China, and
829Brazil and belongs to the Agaricaceae family (Kim et al.
8302009). It is already used in association with standard che-
831motherapeutics in Japan for cancer therapy (Yoshimura
832et al. 2005). Extracts of A. blazei have shown inhibition
833of cell growth and induction of apoptosis in several types
834of tumorigenic cells. Its anti-proliferative effects are partly
835mediated by apoptosis, as reported for different leukemic
836cells, although not in normal cells, which has suggested a
837tumor-selective action (Kim et al. 2009). These effects
838have been confirmed in vivo, with inhibition of tumor
839growth of human acute promyelocytic leukemia cells in
840nude mice following administration of A. blazei extracts
841(Kim et al. 2009). Later, Agaritine was discovered as one
842of the A. blazei components responsible for these anti-
843leukemic properties (Akiyama et al. 2011). Agaritine puri-
844fied from A. blazei directly suppressed cell proliferation
845through induction of apoptosis in several leukemic cell
846lines and showed no effects on normal lymphatic cells
847(Akiyama et al. 2011). However, Agaritine is not the only
848interesting physicochemical agent in these A. blazei ex-
849tracts, with the demonstration of induction of caspase-
850dependent apoptosis in osteosarcoma cells using the poly-
851saccharide ABP-Ia from A. blazei (Wu et al. 2012). This
852study also showed no apoptotic effects for a normal hu-
853man osteoblast cell line, highlighting again the targeted
854action of these agents toward tumorigenic cells (Wu
855et al. 2012). The effects of A. blazei extracts on sarcoma
856have been investigated in vivo using the α-(1–4)-
857glucan-β-(1–6)-glucan-protein complex polysaccharide
858alone or in association with the chemotherapeutic agent
8595-fluorouracil (Gonzaga et al. 2009). These data showed
860strong inhibition of tumor growth and improvement of
861survival in sarcoma-180-bearing mice, while no changes
862were seen for the renal, liver, and hematological parame-
863ters, which indicated the absence of toxicological effects
864in the treated mice (Gonzaga et al. 2009). Of note, the
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865 typical leukopenia due to the use of 5-fluorouracil was
866 abrogated by the association with the polysaccharide de-
867 rived from A. blazei (Gonzaga et al. 2009). It can be
868 concluded that, together with this standard chemotherapeu-
869 tic drug, this polysaccharide was not only responsible for
870 the increment in the anti-tumor effects but also for the
871 decrease in the side effects of the chemotherapy.
872 Another interesting mushroom with anti-cancer properties
873 is Ganoderma sinensis, which is widely used in China as a
874 herbal medicine (Zhou et al. 2007). Among its components,
875 triterpenoid-enriched lipids have emerged due to their immu-
876 nomodulatory and cytotoxic effects. Dose-dependent suppres-
877 sion of proliferation of leukemia and hepatoblastoma cells has
878 been described for a lipid extract of this G. sinensis mush-
879 room, known as GL6. Furthermore, the same GL6 was shown
880 to induce human monocytes and immunosuppressive M2
881 macrophages to release pro-inflammatory cytokines (Yue
882 et al. 2008). This feature makes this mushroom-derived com-
883 pound a novel anti-cancer and immune-modulatory agent
884 (Yue et al. 2008). However, careful clinical studies are still
885required to determine whether these mushrooms do indeed
886provide concrete benefits to patients, due to the toxicological
887problems associated with their use. Additionally, in vivo data
888will be necessary to investigate their molecular mechanisms
889and their safety.
890Another promising anti-tumorigenic natural compound is
891contained in foods such as Garlic (Allium sativum), a bul-
892bous plant that is easy to grown in mild climates. Among its
893components, Diallyl trisulfide and Ajoene are of importance
894not only for their remarkable anti-tumor and cancer-
895preventive effects, as suggested by many in vitro and
896in vivo studies, but also because of their many health ben-
897efits, like improvements to immune-system function, radio-
898protection, and protection against microbial infections
899(BayanBayan et al. 2014). These features make them excel-
900lent candidates for the treatment of pediatric cancers. In-
901deed, Diallyl trisulfide has been demonstrated to arrest
902HepG2 hepatoblastoma cell proliferation by inducing
903caspase-3 activity, enhancing H2O2 levels, and strongly de-
904creasing glutathione levels (Iciek et al. 2012). Moreover,
t4:1 Table 4 Nutraceutical and functional foods that can affect several pathways in pediatric tumors. The main features of the nutraceuticals and functional
foods described in the text are given
Compound Molecular structure Molecular 
formula
Molecular 
weight
(g/mol)
Tumorigenic 
cells and/or mice 
models
Evidence
in vitro
and/or
in vivo
Dose
in-vitro 
( M)
Dose
in-vivo
(mg/kg)
References
Agaritine C12H17N3O4 267.28 Leukemia In vitro 10 (µg/ml) _ (Akiyama, Endo et al. 2011)
Diallyl trisulfide C6H10S3 178.33 Hepatoblastoma
Glioma
In vitro
and
in vivo
(animal 
models)
100-200 0.010-10 (Iciek, Kwiecien et al. 2012)
(Wallace, Haar et al. 2013)
Ajoene C9H14OS3 234.4 Leukemia In vitro 40 _ (Hassan 2004)
Epigallocatechin 
gallate 
C22H18O11 458.37 Neuroblastoma
Hepatoblastoma
In vitro 10-100 _ (Nishimura, Hartomo et al. 
2012)
(Godeke, Maier et al. 2013)
HO
NH
HN
H2N
O
OH
O
S
S
S
S
SS
O
O
O
O
OH
OHOH
OH
OH
OH
HO
OH
Curcumin C21H20O6 368.38 Medulloblastoma
Neuroblastoma
In vitro
and
in vivo
(animal 
models)
10-40 1.0 (Lee, Krauthauser et al. 
2011)
(He, Li et al. 2014)
(Picone, Nuzzo et al. 2014)
Resveratrol C14H12O3 228.24 Leukemia
Neuroblastoma
In vitro
and
in vivo
(animal 
models)
200 20 (Ge, Liu et al. 2013)
(Soto, Hank et al. 2011)
Quercetin C15H10O7 302.23 Neuroblastoma In vitro 20-40 _ (Sugantha Priya, 
Selvakumar et al. 2014)
O
HO
O O
OH
O
OH
HO
OH
O
OH
OH
OH
OOH
HO
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905 anti-cancer effects of Diallyl trisulfide have been shown in
906 glioblastoma, with the reduction of cancer progression in
907 U87/MG ectopic tumors in SCID mice (Wallace, G. C. t
908 et al. 2013). As Diallyl trisulfide has not shown any nega-
909 tive impact on hepatic functions, it can be considered an
910 effective therapeutic agent for the prevention of tumor
911 progression in glioblastoma (Wallace, G. C. t et al.
912 2013). Instead, Ajoene has been shown not only to inhibit
913 cell proliferation and induce caspase-dependent apoptosis
914 of several human myeloid leukemia cells but also to
915 strongly enhance the apoptotic effects of two chemothera-
916 peutic drugs: cytarabine and fludarabine (Hassan 2004).
917 This was observed for the treatment of human CD34-
918 positive resistant myeloid leukemia cells, through enhance-
919 ment of their Bcl-2 inhibitory and caspase-3 activation
920 activities (Hassan 2004). Thus, these food-derived natural
921 compounds can be considered as potent agents with
922 cancer-preventive properties.
923 One of the commonest popular beverages is green
924 tea. The correlation between its consumption and inhi-
925 bition of the growth of a number of cancers is already
926 known (Kanadzu et al. 2006). Green tea contains at
927 least four catechins: epigallocatechin gallate (EGCG),
928 epigallocatechin, epicatechin gallate, and epicatechin
929 (Kanadzu et al. 2006). The most abundant agent in
930 green tea is EGCG. Its anti-cancer effects have been
931 investigated also in neuroblastoma. Tumor-initiating
932 cells were recently identified in neuroblastoma as
933 spheres grown in the serum-free nonadherent culture
934 used for neural-crest stem-cell growth. EGCG inhibited
935 growth and induced apoptosis in BE(2)-C neuroblastoma
936 cells in a dose-dependent manner, although it did not
937 have the same biological effects against such spheres
938 derived from BE(2)-C cells (Nishimura et al. 2012).
939 However, EGCG inhibited the formation of these
940 spheres. So, it will be important to clarify the molecular
941 basis behind the EGCG-sensitive sphere formation in
942 neuroblastoma cells to determine its future clinical ap-
943 plications in children with neuroblastoma (Nishimura
944 et al. 2012). Moreover, EGCG has also been demon-
945 strated to inhibit hepatoblastoma cell growth in a time-
946 dependent and dose-dependent manner while leaving
947 normal fibroblasts unaffected (Godeke et al. 2013).
948 The treated hepatoblastoma cells showed impairment of
949 the WNT signaling pathway (Godeke et al. 2013). This
950 is known to enhance cell proliferation, with subsequent
951 reduction in mRNA levels of its main target genes, c-
952 MYC and CCND1, together with re-expression of the
953 tumor suppressor gene SFRP1, which is usually silenced
954 in these cells, thus impairing its known function: to
955 down-regulate WNT signaling (Godeke et al. 2013).
956 For these reasons, EGCG should be further investigated
957 for its potential clinical applications in the therapy of
958hepatoblastoma, mainly because of its selective actions
959toward tumorigenic cells.
960Functional foods as anti-cancer drugs for pediatric cancer
961treatment
962The available literature has emphasized the potential advan-
963tages of functional foods as chemopreventive agents, both
964alone and in association with standard chemotherapeutics.
965Several studies have focused on the anti-tumorigenic effects
966of Curcumin (also known as Turmeric), a polyphenolic agent
967derived from the Curcuma longa plant. This plant has been
968used in Ayurvedic medicine for centuries because of its non-
969toxic effects and its therapeutic properties, which include anti-
970cancer activity (Villegas et al. 2011). Indeed, Curcumin has
971been shown to have anti-proliferative effects in multiple can-
972cers, including pediatric tumors, through targeting several
973pathways involved in tumorigenesis, including the MAPK,
974PI3K, and NFκB signaling pathways, and impairing metasta-
975sis formation (Heger et al. 2014);(Villegas et al. 2011). One of
976the most interesting features that makes Curcumin an ideal
977compound to treat pediatric brain tumors is that it can cross
978the blood–brain barrier due to its high lipophilic properties
979(Marchiani et al. 2014). In addition, Curcumin has been
980shown to induce apoptosis in vitro in human medulloblastoma
981cells, and to reduce tumor growth, thus increasing survival
982rates in vivo in mouse models of medulloblastoma, without
983showing any toxic effects (Lee et al. 2011). Curcumin has
984been shown to bind the phosphorylated form of the protein
985Cdc27, and the data that have been reported indicate that due
986to the phosphorylated Cdc27, the fast-growing medulloblas-
987toma cells were more susceptible to Curcumin-induced cell
988death than those that only had non-phosphorylated Cdc27
989(Lee and Langhans 2012). These results not only provided a
990possible explanation for the selective mechanism of action of
991Curcumin, but they also suggested that the phosphorylation
992status of Cdc27 might be developed as a biomarker to predict
993which patients might respond favorably to Curcumin-based
994cancer therapy (Lee and Langhans 2012). Recently, the im-
995pairment of the Wnt/β-catenin signaling pathway by
996Curcumin in medulloblastoma cells was reported (He et al.
9972014). In particular, this led to GSK-3β activation and subse-
998quent nuclear β-catenin down-regulation (He et al. 2014).
999Moreover, Curcumin anti-tumorigenic effects were also
1000shown in neuroblastoma cells (Picone et al. 2014). These
1001treated cells showed a rapid increase in reactive oxygen spe-
1002cies, decrease in mitochondrial membrane potential, increase
1003in the pro-apoptotic protein Bcl-2-associated death promoter
1004(BAD), inhibition of Akt signaling, and activation of the pro-
1005apoptotic proteins p27, Bim, and the Fas-L tumor necrosis
1006factor family protein (Picone et al. 2014). All of these events
1007together suggest the induction of apoptosis in these neuroblas-
1008toma cells (Picone et al. 2014). Indeed, altogether, these
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1009 results provide evidence for considering Curcumin as an ideal
1010 therapeutic agent for children with brain tumors.
1011 Additional attention has been given to Resveratrol (i.e.,
1012 trans-3, 5, 40-trihydroxystilbene), which is a phytoalexin that
1013 is found in many plants, including those often consumed by
1014 human, such as grapes, peanuts, and berries (Carter et al.
1015 2014). It is not only found in these plants but also in processed
1016 products from them, like wine (Carter et al. 2014). Several
1017 in vitro studies have shown that Resveratrol has multiple
1018 anti-tumorigenic effects through the promotion of cell-cycle
1019 arrest and induction of apoptosis of tumorigenic cells, by in-
1020 hibition of tumor growth and cell motility (Carter et al. 2014).
1021Q27 The anti-leukemic effects of were reported by Ge et al., who
1022 showed that Resveratrol induces cell-cycle arrest, apoptosis,
1023 and autophagy in acute T-lymphoblastic leukemia cells
1024 through inhibition of the Akt/mTOR/p70S6K/4E-BP1 path-
1025 way and activation of the p38-MAPK signaling pathway
1026 (Ge et al. 2013). Furthermore, the anti-tumor effects of Res-
1027 veratrol have also been described in in vivo neuroblastoma
1028 studies (Soto et al. 2011). The combination of Resveratrol
1029and immunocytokine regimens has been reported to enhance
1030anti-tumor activity and improve tumor-free survival in neuro-
1031blastoma mice models, while Resveratrol alone only induced
1032tumor regression in primary sites. Indeed, the mice treated
1033with Resveratrol alone developed tumor recurrence and me-
1034tastasis (Soto et al. 2011). These results suggest a role for
1035Resveratrol in the treatment of acute lymphoblastic leukemia
1036and neuroblastoma.
1037Finally, the flavonol Quercetin is an interesting natural
1038compound that is contained in different types of fruit (e.g.,
1039apples, berries), vegetables (e.g., brassica, onion), black tea,
1040red wine, and many seeds, nuts, flowers, barks, and leaves
1041(Sugantha Priya et al. 2014). As Quercetin has been shown
1042to have many interesting biological properties, including as an
1043anti-oxidant, anti-inflammatory, and anti-neoplastic, it appears
1044to be a candidate for prevention and treatment of childhood
1045tumors. Its anti-tumorigenic activity has been studied in neu-
1046roblastoma cells (Sugantha Priya et al. 2014). Here, Quercetin
1047was shown to retain its ability to induce caspase-dependent
1048apoptosis in murine neuroblastoma neuro2a cell lines
Fig. 1 Intracellular pathways altered by natural compounds in childhood
malignancies. Illustration of the novel natural compounds that have been
identified recently as having negative effects on intracellular signaling
pathways involved in angiogenesis and metastasis formation in
pediatric tumors. The colors of the arrows represent the types of cancer
(see color legend); dashed lines indicate those compounds identified from
literature searches into nutraceuticals and functional foods
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1049 (Sugantha Priya et al. 2014). Further studies are required to
1050 investigate the exact mechanism of Quercetin action, toward
1051 the development of novel therapeutic approaches in neuro-
1052 blastoma treatment in vivo.
1053 Conclusions
1054 In recent years, great contributions to childhood cancer thera-
1055 py have been made through the use of natural compounds.
1056 Despite the technological progress in combinatorial chemistry,
1057 synthetic anti-cancer drugs continue to be responsible for non-
1058 selective killing of cells. As natural compounds have been
1059 shown to offer therapeutic actions with low cytotoxicity in
1060 several studies, and due to their chemical diversity, structural
1061 complexity, and biological potency, they should be considered
1062 further as major sources of drug leads, especially for the treat-
1063 ment of childhood cancers. These compounds are still provid-
1064 ing important impacts on drug discovery as they act as tem-
1065 plates for the construction of novel nature-derived molecules,
1066 with the challenge being to enhance the biological properties
1067 and reduce the side effects.
1068 Despite recent progress in pediatric tumor treatment, cancer
1069 continues to be the major reason for childhood mortality, and
1070 conventional therapies are responsible for poor health-related
1071 quality of life and chronic health conditions in childhood can-
1072 cer survivors. Due to their potential to affect every tissue,
1073 current non-selective therapies might have indeterminate
1074 long-term effects in young children. Thus, future studies
1075 should better identify and manage the functional outcomes
1076 of childhood cancer survivors because of their emotional dis-
1077 tress (e.g., depressive symptoms, anxiety, increased somatiza-
1078 tion) and their reduced healthcare due to long-term side effects
1079 of current therapies (Kinahan et al. 2012). Thus, natural com-
1080 pounds, including dietary factors, nutraceuticals, and especial-
1081 ly functional foods (e.g., Quercetin, Resveratrol, EGCG,
1082 Diallyl trisulfide, Ajoene), are of significance here. As a result
1083 of their low toxicity and targeting of a wide range of signaling
1084 pathways involved in tumorigenesis, such natural compounds
1085 can be used to decrease these therapy-related side effects in
1086 children (as shown in Fig. 1).
1087 The introduction of such bioactive, nature-derived agents
1088 into clinics has changed the outcome of several types of pedi-
1089 atric cancers. Nevertheless, many efforts need to be focused
1090 on drug discovery of further new natural compounds, to iden-
1091 tify new drugs derived from novel natural products. This will
1092 also increase their efficacy and reduce their side effects in
1093 children, with the need to also facilitate their handling and
1094 tolerability by developing oral regimens and/or liposomal for-
1095 mulation. Plants still represent a great source for natural com-
1096 pounds in drug discovery but microorganisms and marine-
1097 derived compounds will have governing roles in the future,
1098 with a large number of promising molecules that are already
1099undergoing clinical development as anti-cancer agents for
1100childhood tumors.
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